Supplementary Materials

This PDF file includes:

  • Materials and Methods
  • Fig. S1. In vitro optimization of epigenetic genome engineering tools to enable NaV1.7 repression.
  • Fig. S2. Quantification of DRG transduction efficiencies via AAVs and carrageenan-induced inflammation in mice.
  • Fig. S3. Benchmarking of in situ repression of NaV1.7 using ZFP-KRAB with established small-molecule drug gabapentin.
  • Fig. S4. Examining the safety of in situ repression of NaV1.7 via ZFP-KRAB and KRAB-dCas9.
  • Fig. S5. Neuropathology analyses of DRGs targeted via AAVs.
  • Fig. S6. Genome-wide analysis of gene expression in zinc finger or CRISPR-treated Neuro2a cells.
  • Fig. S7. Multielectrode array recordings of DRG neurons transduced with AAV9-Zinc-Finger-4 show reduced response to heat.
  • Table S1. CRISPR-Cas9 gRNA spacer sequences.
  • Table S2. ZFP genomic target sequences.
  • Table S3. qPCR primers.
  • References (7394)

[Download PDF]